A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) (NCT06653153)
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Who can join: Review the eligibility criteria below.
Location: Parkway Medical Center — Birmingham, Alabama
Age range: 55 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (262 Sites)
Showing the first 25 of 262 sites.
- Parkway Medical Center — Birmingham, Alabama
- MD First Research - Chandler — Chandler, Arizona
- Care Access - 801 South Power Road, Mesa — Mesa, Arizona
- Banner Alzheimer's Institute — Phoenix, Arizona
- Banner Alzheimer's Institute Tucson — Tucson, Arizona
- Neuro-Pain Medical Center — Fresno, California
- Care Access - Huntington Beach — Huntington Beach, California
- Inglewood Clinical — Inglewood, California
- Irvine Clinical Research — Irvine, California
- Healthy Brain Clinic — Long Beach, California
- Riverside Clinical — Riverside, California
- Clinical Trials Research — Sacramento, California
- Artemis Institute for Clinical Research — San Diego, California
- Sharp Neurocognitive Research Center — San Diego, California
- Ray Dolby Brain Health Center — San Francisco, California
- The Neuron Clinic - San Marcos — San Marcos, California
- Syrentis Clinical Research — Santa Ana, California
- Providence Medical Foundation — Santa Rosa, California
- California Neuroscience Research, LLC — Sherman Oaks, California
- Care Access - Aurora — Aurora, Colorado
- Mountain Neurological Research Center — Basalt, Colorado
- Alpine Clinical Research Center — Boulder, Colorado
- CenExel Rocky Mountain Clinical Research — Englewood, Colorado
- Invicro — New Haven, Connecticut
- Ki Health Partners, LLc, dba New England Institute for Clinical Research — Stamford, Connecticut
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer's Disease
- Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia — Calgary, Alberta
- A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology — Clermont, Florida
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease — Phoenix, Arizona
- DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease — Birmingham, Alabama
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) — Chandler, Arizona
Explore by condition: All Alzheimer's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.